Dr.MetabolicMD said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.
TrialNerd_Beth said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
Saving this. It is the first explanation that did not require me to already understand it. I will report back once I have actually tried it.
Dr.MetabolicMD said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.
Worth separating that from compounded supply, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
I would rather be corrected than agreed with, if it comes to it.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne concrete data point for the thread. Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.